Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Adalimumab was first approved in the U.S. for the treatment of aforementioned medical conditions. Currently, this is marketed in more than 60 countries. However, owing to the biologic nature of the drug, it results in high cost and low accessibility in emerging economies such as LATAM and Asia Pacific. On the other hand, with the probable entry of the adalimumab biosimilars post the patent expiry the low costs up to less than 25% to 35% of the originator drugs will boost the uptake and prescription of adalimumab for the treatment of above mentioned medical conditions.
The report details the trend, potential and market size of LATAM Adalimumab market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of LATAM Adalimumabmarket, defines the market attractiveness level of LATAM Adalimumab market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of LATAM Adalimumab industry, describes the types of LATAM Adalimumab market, the applications of major players and the market size, and deeply analyzes the current situation of the global LATAM Adalimumab market and the development prospects and opportunities of LATAM Adalimumab industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global LATAM Adalimumab market in Chapter 13.
By Player:
Boehringer Ingelheim GmbH
Novartis AG
By Type:
Oral Type
Injection Type
By End-User:
Rheumatoid Arthritis
Psoriasis
Crohn’s Disease
Ulcerative Colitis
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 LATAM Adalimumab Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 LATAM Adalimumab Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 LATAM Adalimumab Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 LATAM Adalimumab Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise LATAM Adalimumab Market Analysis and Outlook to 2022
-
7.1 Global LATAM Adalimumab Consumption (2017-2022)
-
7.2 United States LATAM Adalimumab Consumption (2017-2022)
-
7.3 Europe LATAM Adalimumab Consumption (2017-2022)
-
7.4 China LATAM Adalimumab Consumption (2017-2022)
-
7.5 Japan LATAM Adalimumab Consumption (2017-2022)
-
7.6 India LATAM Adalimumab Consumption (2017-2022)
-
7.7 South Korea LATAM Adalimumab Consumption (2017-2022)
8 Region and Country-wise LATAM Adalimumab Market Analysis and Outlook to 2028
-
8.1 Global LATAM Adalimumab Consumption Forecast (2022-2028)
-
8.2 United States LATAM Adalimumab Consumption Forecast (2022-2028)
-
8.3 Europe LATAM Adalimumab Consumption Forecast (2022-2028)
-
8.4 China LATAM Adalimumab Consumption Forecast (2022-2028)
-
8.5 Japan LATAM Adalimumab Consumption Forecast (2022-2028)
-
8.6 India LATAM Adalimumab Consumption Forecast (2022-2028)
-
8.7 South Korea LATAM Adalimumab Consumption Forecast (2022-2028)
9 Global LATAM Adalimumab Market Outlook by Types and Applications to 2022
-
9.1 Global LATAM Adalimumab Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Oral Type Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Injection Type Consumption and Growth Rate (2017-2022)
-
9.2 Global LATAM Adalimumab Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Psoriasis Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Crohn’s Disease Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Others Consumption and Growth Rate (2017-2022)
10 Global LATAM Adalimumab Market Outlook by Types and Applications to 2028
-
10.1 Global LATAM Adalimumab Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Oral Type Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Injection Type Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global LATAM Adalimumab Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Psoriasis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Crohn’s Disease Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global LATAM Adalimumab Import and Export Analysis (Top 5 Countries)
-
11.1 Global LATAM Adalimumab Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global LATAM Adalimumab Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 LATAM Adalimumab Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global LATAM Adalimumab Market Competitive Analysis
-
14.1 Boehringer Ingelheim GmbH
-
14.1.1 Boehringer Ingelheim GmbH Company Details
-
14.1.2 Boehringer Ingelheim GmbH LATAM Adalimumab Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 Boehringer Ingelheim GmbH LATAM Adalimumab Product and Service
-
14.2 Novartis AG
-
14.2.1 Novartis AG Company Details
-
14.2.2 Novartis AG LATAM Adalimumab Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Novartis AG LATAM Adalimumab Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of LATAM Adalimumab
-
Figure LATAM Adalimumab Picture
-
Table Global LATAM Adalimumab Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global LATAM Adalimumab Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global LATAM Adalimumab Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global LATAM Adalimumab Consumption by Country (2017-2022)
-
Figure United States LATAM Adalimumab Consumption and Growth Rate (2017-2022)
-
Table Europe LATAM Adalimumab Consumption and Growth Rate (2017-2022)
-
Figure China LATAM Adalimumab Consumption and Growth Rate (2017-2022)
-
Figure Japan LATAM Adalimumab Consumption and Growth Rate (2017-2022)
-
Figure India LATAM Adalimumab Consumption and Growth Rate (2017-2022)
-
Figure South Korea LATAM Adalimumab Consumption and Growth Rate (2017-2022)
-
Figure Global LATAM Adalimumab Consumption Forecast by Country (2022-2028)
-
Figure United States LATAM Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe LATAM Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure China LATAM Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan LATAM Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure India LATAM Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea LATAM Adalimumab Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Oral Type Consumption and Growth Rate (2017-2022)
-
Figure Global Injection Type Consumption and Growth Rate (2017-2022)
-
Figure Global Rheumatoid Arthritis Consumption and Growth Rate (2017-2022)
-
Figure Global Psoriasis Consumption and Growth Rate (2017-2022)
-
Figure Global Crohn’s Disease Consumption and Growth Rate (2017-2022)
-
Figure Global Ulcerative Colitis Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Oral Type Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Injection Type Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Rheumatoid Arthritis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Psoriasis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Crohn’s Disease Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Ulcerative Colitis Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global LATAM Adalimumab Import by Region (Top 5 Countries) (2017-2028)
-
Table Global LATAM Adalimumab Export by Region (Top 5 Countries) (2017-2028)
-
Table Boehringer Ingelheim GmbH (Foundation Year, Company Profile and etc.)
-
Table Boehringer Ingelheim GmbH LATAM Adalimumab Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim GmbH LATAM Adalimumab Product and Service
-
Table Novartis AG (Foundation Year, Company Profile and etc.)
-
Table Novartis AG LATAM Adalimumab Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis AG LATAM Adalimumab Product and Service
-
